Amalgamated Bank Sells 207 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Amalgamated Bank cut its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 1.6% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 12,477 shares of the company’s stock after selling 207 shares during the quarter. Amalgamated Bank’s holdings in Medpace were worth $4,145,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of MEDP. Iron Triangle Partners LP bought a new position in shares of Medpace during the 3rd quarter worth approximately $64,371,000. Wellington Management Group LLP grew its holdings in Medpace by 36.0% in the third quarter. Wellington Management Group LLP now owns 415,255 shares of the company’s stock worth $138,612,000 after purchasing an additional 109,886 shares during the last quarter. DF Dent & Co. Inc. increased its position in shares of Medpace by 189.9% during the third quarter. DF Dent & Co. Inc. now owns 161,298 shares of the company’s stock worth $53,841,000 after purchasing an additional 105,659 shares in the last quarter. Caisse DE Depot ET Placement DU Quebec purchased a new stake in shares of Medpace during the 3rd quarter valued at $23,321,000. Finally, Swedbank AB boosted its position in shares of Medpace by 245.5% in the 4th quarter. Swedbank AB now owns 77,400 shares of the company’s stock worth $25,715,000 after purchasing an additional 55,000 shares in the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Medpace Stock Performance

Shares of MEDP stock opened at $327.32 on Friday. Medpace Holdings, Inc. has a fifty-two week low of $302.01 and a fifty-two week high of $459.77. The firm has a market capitalization of $9.97 billion, a PE ratio of 25.92, a P/E/G ratio of 3.81 and a beta of 1.36. The stock’s 50-day simple moving average is $342.66 and its 200-day simple moving average is $345.71.

Medpace (NASDAQ:MEDP) last issued its earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. Sell-side analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Robert W. Baird upped their target price on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research report on Monday, January 27th. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $381.44.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.